Detail akcie CNS Pharma Rg online

Business Summary: CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Financial Summary: BRIEF: For the three months ended 31 March 2025, CNS Pharmaceuticals Inc revenues was not reported. Net loss increased 21% to $4.3M. Higher net loss reflects Research and development increase of 33% to $3.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1017.14 to -$1.58.